Thanks wop though weirdly enough I find the estimate that the...

Thanks wop though weirdly enough I find the estimate that the share price might more than double underwhelming. I cannot fathom how a company with a disruptive product like ColoSTAT in a market sector measured in tens of billions of dollars could be bought for as little as some hundred million dollars. Blood tests are preferred over stool tests by 70% of those surveyed and ColoSTAT is 35% more accurate than FIT ... what else is there to know?

I haven't rolled out this saying for a while but I hope it is pertinent to biosciences in this instance:

“In economics, things take longer to happen than you think they will, and then they happen faster than you thought they could.”

― Rudiger Dornbusch